English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

At the most recent Genitourinary Cancers Symposium in Orlando February 2015, a task force was organized to discuss issues in trial design in non-muscle invasive bladder cancer. Our aim was to provide further clarification regarding disease states following treatment of patients with intravesical BCG and to determine what events constitute progression following any treatment for non-muscle invasive bladder cancer (NMIBC). The panelists were asked to address a number of specific Tasks, enumerated below.

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG